INCY - Incyte Q3 2021 Earnings Preview

Incyte (NASDAQ:INCY) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, before market open. The consensus EPS Estimate is $0.75 (+226.1% Y/Y) and the consensus Revenue Estimate is $744.53M (+20.0% Y/Y). In August, Seeking Alpha contributor Qingshan Capital Management called Incyte "undervalued" and said that the company "appears to see that growth is returning to pre-covid levels". Recently, the U.S. FDA accepted to review Incyte's NDA for parsaclisib, with a PDUFA target action date of August 30, 2022. Incyte had reported Q2 2021 results and provides an update on its development portfolio, in August. Over the last 2 years, INCY has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time. Over the last 3 months, EPS estimates have seen 7 upward revisions and 4 downward. Revenue estimates have seen 8 upward revisions and 6 downward. The company's shares have fallen more than 22% year to  date.

For further details see:

Incyte Q3 2021 Earnings Preview